Histogen — Investor Presentation (August 2020)
23 slides from Histogen's investor presentation, Aug 7, 2020
Slide 1: Restoring Function Enhancing Lives
Restoring Function Enhancing Lives August 7, 2020 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions of the Privat
Slide 3: Developing first-in-class restorative therapeutics
Histogen is developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function Proprietary hypoxia-generated growth factor technology platform Strong intellectual property portfolio Pipeline focused on multiple thera
Slide 4: Technology Platform Yields Multiple Product Candidate Opportunities
Technology Platform Yields Multiple Product Candidate Opportunities Growing fibroblast cells under simulated embryonic conditions to induce them to become multipotent with stem cell like properties Spectrum of products created from core technology Human Multipotent Cell Conditioned Media, or CCM con
Slide 5: Robust Pipeline
Robust Pipeline Preclinical Phase 1 Phase 2 Phase 3 Marketed/Partner CCM Cosmetics HST 001 Hair Growth (HSC) HST 002 Dermal Filler (hECM + Lidocaine) HST 003 Joint Cartilage (hECM) HST 004 Spine (CCM) World Wide Rights China
Slide 6: Large Addressable Markets
Large Addressable Markets 1 Histogen estimate, U.S. only 2 Histogen market research, U.S. only $3.6 billion ——— Annual spend on hair loss, targeting men aged 30-49 (1) $1.1 billion ——— Annual spend on dermal fillers, 1.2 million patients receiving dermal fillers annually (2) (1) $0.9 billion ——— Ann
Slide 7: HST Hair Growth
HST 001 Hair Growth A minimally-invasive treatment to promote new hair growth where existing treatments only reduce hair loss
Slide 8: HST Hair Growth Overview
HST 001 Hair Growth Overview If approved, HST 001, would be the only product to grow new terminal hairs. Current approved products preserve existing hair to reduce overall hair loss Human proteins and growth factors stimulate resting hair follicles to produce new cosmetically-relevant hair Minimally
Slide 9: Three Completed Company-Sponsored Clinical Trials
Three Completed Company-Sponsored Clinical Trials Pilot in male pattern hair loss Phase 1a in male pattern hair loss Phase 1a in female diffuse hair loss Strong Safety Profile No kidney, liver or bone marrow toxicity No severe adverse events Treatment well tolerated across all subjects Statistically
Slide 10: HST 001 Phase 1b/2a Protocol – Enrollment Complete
Objective: Optimal dosing of HSC in male pattern hair loss Enrollment Criteria: 36 men, aged 20-55 Male pattern hair loss (Norwood-Hamilton 2A, 3, 3V, 4, 4A) Treatment Regimen: 20 injections of HSC week 0, week 6, week 12 20 injections of placebo (PBS) week 0, week 6, week 12 Endpoints: Adverse even
Slide 11: Phase 1b/2a Study Data Success Criteria
Study Endpoints: No serious adverse events or indicators of of toxicity Statistically significant improvement in the following parameters based on Canfield Macrophotography analysis of subjects at week 18: Absolute change in total hair count vs. baseline at week 18 (at least 18 more hairs in target
Slide 12: hECM Fillers
hECM Fillers Human-derived collagen and extracellular matrix dermal fillers for delivering longer-lasting treatment of facial folds and wrinkles
Slide 13: HST Dermal Filler Overview
HST 002 Dermal Filler Overview If approved, HST 002, would be the only filler providing all-human and naturally produced collagen with dermal matrix proteins hECM filler provides the natural proteins found in young, healthy skin all-human and naturally produced collagen with dermal matrix proteins P
Slide 14: HST Dermal Filler Phase Study Protocol
HST 002 Dermal Filler Phase 1 Study Protocol Objective: Evaluate human extracellular matrix (hECM) as a dermal filler in direct comparison to Restylane-L in moderate to severe nasolabial folds Enrollment Criteria: 22 patients - men and women; 2 clinical sites Treatment Regimen: hECM filler up to 3 m
Slide 15: hECM Joint Cartilage
hECM Joint Cartilage Human extracellular matrix regenerates hyaline cartilage for the treatment of articular cartilage defects with a novel malleable scaffold that stimulates the body’s own stem cells.
Slide 16: HST Joint Cartilage Overview
HST 003 Joint Cartilage Overview If approved, HST 003, would be the only product to regenerate hyaline cartilage which could potentially improve functionality and mobility as well as provide reduction in inflammation, potentially reducing pain. Malleable scaffold applied to full-thickness chondral l
Slide 17: HST Joint Cartilage Preclinical Proof-of-Concept
HST 003 Joint Cartilage Preclinical Proof-of-Concept Rat model Untreated defects (10) - extensive fibrotic tissue and no articular cartilage at 6 weeks Treated defects (10) - congruent and smooth cartilage regeneration and integration with surrounding cartilage at 6 weeks (O’Driscoll p<0.001) Rabbit
Slide 18: HST Joint Cartilage Phase 1/2 Protocol
HST 003 Joint Cartilage Phase 1/2 Protocol Objective: Evaluate the safety of hECM paste delivered arthroscopically during microfracture procedure Enrollment Criteria: 15 patients who are candidates for microfracture surgery Recent focal cartilage defects of 2 - 4cm2 in the knee 3 sites: Walter Reed
Slide 19: Summary and Leadership
Summary and Leadership
Slide 20: Key Clinical Development Milestones
2020 2020 2021 Q2 Q3 Q4 Q1 Q2 Q3 Q4 HST 001 HST 002 HST 003 HST 004 Key Clinical Development Milestones Initiated Phase 1b/2a study Submit IND Initiate Phase 1 trial Initiate Phase 1/2 study Top-line data readout Submit IND Top-line data readout Top-line data readout (June 2020)
Slide 21: Accomplished Leadership Team
Accomplished Leadership Team Gail Naughton, Ph.D. Founder/Chief Scientific Officer Martin Latterich, Ph.D. Sr. VP of Technical Operations Richard Pascoe President and CEO Susan Knudson Chief Financial Officer
Slide 22: Positioned for Growth
Positioned for Growth Validated Technology: Demonstrated pre-clinical/clinical proof of concept with HSC and hECM CCM marketed by Allergan in their SkinMedica TNS A+ brand Strategic Pipeline: Targeting high-value markets with potential first-in-class product candidates Clinical development programs
Slide 23: Restoring Function Enhancing Lives
Restoring Function Enhancing Lives August 7, 2020